Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis

Sexually transmitted diseases (STDs) are a major global health issue. Approximately 250 million new cases of STDs occur each year globally. Currently, only three STDs (human papillomavirus (HPV), hepatitis A, and hepatitis B) are preventable by vaccines. Vaccines for other STDs, including gonorrhea,...

Full description

Bibliographic Details
Main Authors: Christiane Chbib, Sarthak M. Shah, Rikhav P. Gala, Mohammad N. Uddin
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/9/11/1245
_version_ 1797508326506889216
author Christiane Chbib
Sarthak M. Shah
Rikhav P. Gala
Mohammad N. Uddin
author_facet Christiane Chbib
Sarthak M. Shah
Rikhav P. Gala
Mohammad N. Uddin
author_sort Christiane Chbib
collection DOAJ
description Sexually transmitted diseases (STDs) are a major global health issue. Approximately 250 million new cases of STDs occur each year globally. Currently, only three STDs (human papillomavirus (HPV), hepatitis A, and hepatitis B) are preventable by vaccines. Vaccines for other STDs, including gonorrhea, chlamydia, and syphilis, await successful development. Currently, all of these STDs are treated with antibiotics. However, the efficacy of antibiotics is facing growing challenge due to the emergence of bacterial resistance. Therefore, alternative therapeutic approaches, including the development of vaccines against these STDs, should be explored to tackle this important global public health issue. Mass vaccination could be more efficient in reducing the spread of these highly contagious diseases. Bacterial outer membrane vesicle (OMV) is a potential antigen used to prevent STDs. OMVs are released spontaneously during growth by many Gram-negative bacteria. They present a wide range of surface antigens in native conformation that possess interesting properties such as immunogenicity, adjuvant potential, and the ability to be taken up by immune cells, all of which make them an attractive target for application as vaccines against pathogenic bacteria. The major challenge associated with the use of OMVs is its fragile structure and stability. However, a particulate form of the vaccine could be a suitable delivery system that can protect the antigen from degradation by a harsh acidic or enzymatic environment. The particulate form of the vaccine can also act as an adjuvant by itself. This review will highlight some practical methods for formulating microparticulate OMV-based vaccines for STDs.
first_indexed 2024-03-10T05:00:31Z
format Article
id doaj.art-c9a9593b4fb84fd4b03c350c0db319e0
institution Directory Open Access Journal
issn 2076-393X
language English
last_indexed 2024-03-10T05:00:31Z
publishDate 2021-10-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj.art-c9a9593b4fb84fd4b03c350c0db319e02023-11-23T01:51:37ZengMDPI AGVaccines2076-393X2021-10-01911124510.3390/vaccines9111245Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and SyphilisChristiane Chbib0Sarthak M. Shah1Rikhav P. Gala2Mohammad N. Uddin3Department of Pharmaceutical Science, College of Pharmacy, Larkin University, Miami, FL 33169, USADepartment of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USAFraunhofer USA, Center Mid-Atlantic, Biotechnology Division, Newark, DE 19702, USADepartment of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, GA 30341, USASexually transmitted diseases (STDs) are a major global health issue. Approximately 250 million new cases of STDs occur each year globally. Currently, only three STDs (human papillomavirus (HPV), hepatitis A, and hepatitis B) are preventable by vaccines. Vaccines for other STDs, including gonorrhea, chlamydia, and syphilis, await successful development. Currently, all of these STDs are treated with antibiotics. However, the efficacy of antibiotics is facing growing challenge due to the emergence of bacterial resistance. Therefore, alternative therapeutic approaches, including the development of vaccines against these STDs, should be explored to tackle this important global public health issue. Mass vaccination could be more efficient in reducing the spread of these highly contagious diseases. Bacterial outer membrane vesicle (OMV) is a potential antigen used to prevent STDs. OMVs are released spontaneously during growth by many Gram-negative bacteria. They present a wide range of surface antigens in native conformation that possess interesting properties such as immunogenicity, adjuvant potential, and the ability to be taken up by immune cells, all of which make them an attractive target for application as vaccines against pathogenic bacteria. The major challenge associated with the use of OMVs is its fragile structure and stability. However, a particulate form of the vaccine could be a suitable delivery system that can protect the antigen from degradation by a harsh acidic or enzymatic environment. The particulate form of the vaccine can also act as an adjuvant by itself. This review will highlight some practical methods for formulating microparticulate OMV-based vaccines for STDs.https://www.mdpi.com/2076-393X/9/11/1245antibioticchlamydiagonorrheasyphilissexually transmitted diseases (STDs)microparticulate
spellingShingle Christiane Chbib
Sarthak M. Shah
Rikhav P. Gala
Mohammad N. Uddin
Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis
Vaccines
antibiotic
chlamydia
gonorrhea
syphilis
sexually transmitted diseases (STDs)
microparticulate
title Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis
title_full Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis
title_fullStr Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis
title_full_unstemmed Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis
title_short Potential Applications of Microparticulate-Based Bacterial Outer Membrane Vesicles (OMVs) Vaccine Platform for Sexually Transmitted Diseases (STDs): Gonorrhea, Chlamydia, and Syphilis
title_sort potential applications of microparticulate based bacterial outer membrane vesicles omvs vaccine platform for sexually transmitted diseases stds gonorrhea chlamydia and syphilis
topic antibiotic
chlamydia
gonorrhea
syphilis
sexually transmitted diseases (STDs)
microparticulate
url https://www.mdpi.com/2076-393X/9/11/1245
work_keys_str_mv AT christianechbib potentialapplicationsofmicroparticulatebasedbacterialoutermembranevesiclesomvsvaccineplatformforsexuallytransmitteddiseasesstdsgonorrheachlamydiaandsyphilis
AT sarthakmshah potentialapplicationsofmicroparticulatebasedbacterialoutermembranevesiclesomvsvaccineplatformforsexuallytransmitteddiseasesstdsgonorrheachlamydiaandsyphilis
AT rikhavpgala potentialapplicationsofmicroparticulatebasedbacterialoutermembranevesiclesomvsvaccineplatformforsexuallytransmitteddiseasesstdsgonorrheachlamydiaandsyphilis
AT mohammadnuddin potentialapplicationsofmicroparticulatebasedbacterialoutermembranevesiclesomvsvaccineplatformforsexuallytransmitteddiseasesstdsgonorrheachlamydiaandsyphilis